Pollack Charles V, Sites Frank D, Shofer Frances S, Sease Keara L, Hollander Judd E
Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA.
Acad Emerg Med. 2006 Jan;13(1):13-8. doi: 10.1197/j.aem.2005.06.031. Epub 2005 Dec 19.
Patients presenting with chest pain or related symptoms suggestive of myocardial ischemia, without ST-segment elevation (NSTE) on their presenting electrocardiograms, often present a diagnostic challenge in the emergency department (ED). Prompt and accurate risk stratification to identify those patients with NSTE chest pain who are at highest risk for adverse events is essential, however, to optimal management. Although validated and used frequently in patients already enrolled in acute coronary syndrome trials, the Thrombolysis in Myocardial Infarction (TIMI) risk score never has been examined for its value in risk stratification in an all-comers, non-trial-based ED chest pain population.
An analysis of an ED-based prospective observational cohort study was conducted in 3,929 adult patients presenting with chest pain syndrome and warranting evaluation with an electrocardiogram. These patients had TIMI risk scores determined at ED presentation. The main outcome was the composite of death, acute myocardial infarction (MI), and revascularization within 30 days.
The TIMI risk score at ED presentation successfully risk-stratified this unselected cohort of chest pain patients with respect to 30-day adverse outcome, with a range from 2.1%, with a score of 0, to 100%, with a score of 7. The highest correlation of an individual TIMI risk indicator to adverse outcome was for elevated cardiac biomarker at admission. Overall, the score had similar performance characteristics to that seen when applied to other databases of patients enrolled in clinical trials and registries using a 14-day end point.
The TIMI risk score may be a useful tool for risk stratification of ED patients with chest pain syndrome.
心电图上无ST段抬高(NSTE)但出现胸痛或提示心肌缺血相关症状的患者,在急诊科(ED)常面临诊断挑战。然而,为了实现最佳管理,迅速且准确地进行风险分层以识别那些发生不良事件风险最高的NSTE胸痛患者至关重要。尽管心肌梗死溶栓(TIMI)风险评分在已纳入急性冠状动脉综合征试验的患者中经过验证且经常使用,但从未在基于急诊科所有患者、非试验性的胸痛人群中检验其在风险分层中的价值。
对一项基于急诊科的前瞻性观察性队列研究进行分析,该研究纳入了3929例出现胸痛综合征且需进行心电图评估的成年患者。这些患者在急诊科就诊时确定了TIMI风险评分。主要结局是30天内死亡、急性心肌梗死(MI)和血运重建的复合结局。
急诊科就诊时的TIMI风险评分成功地对这一未经选择的胸痛患者队列进行了30天不良结局的风险分层,评分范围从0分时的2.1%到7分时的100%。个体TIMI风险指标与不良结局的最高相关性是入院时心脏生物标志物升高。总体而言,该评分的表现特征与应用于其他使用14天终点的临床试验和注册研究患者数据库时相似。
TIMI风险评分可能是对急诊科胸痛综合征患者进行风险分层的有用工具。